Cyclin D1 and the resistance landscape of HIF2 inhibition in clear-cell renal cell carcinoma: Insights from a mini-review
Biochemical and Biophysical Research Communications · 2026
DOI: 10.1016/j.bbrc.2026.153305 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Zhenbang Zhong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Science Research Center, Hui…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Basic Helix-Loop-Helix Proteins, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Shanghai Key Discipline Construction Project.
Abstract (Originalsprache)
Clear-cell renal cell carcinoma (ccRCC) is primarily driven by VHL inactivation and subsequent stabilization of hypoxia-inducible factor 2α (HIF2α). The recent approval of the HIF2 inhibitor belzutifan represents a landmark advance, yet both primary and acquired resistance remain major barriers. In this mini-review, we summarize emerging insights into the molecular basis of HIF2 inhibitor response and resistance, with a particular focus on Cyclin D1 as a key downstream effector linking HIF2 signaling to cell-cycle progression. Persistent Cyclin D1 expression, as well as functional compensation by Cyclin D2, underlies diverse resistance phenotypes. Furthermore, the dual contribution of Cyclin D1-driven proliferation and VEGF-mediated angiogenesis explains why durable responses require combined suppression of intracellular and microenvironmental pathways. We also discuss translational opportunities, including HIF2 inhibitor combinations with CDK4/6 inhibitors and anti-VEGF agents, and highlight CCND1/CCND2 as potential biomarkers. Finally, we outline future challenges and perspectives for precision-based, mechanism-driven therapy in ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Science Research Center, Huizhou Central People's Hospital, Huizhou, Guangdong, China.
- Department of Urology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, China.
- Science Research Center, Huizhou Central People's Hospital, Huizhou, Guangdong, China. Electronic address: Tian_Yu@ben.edu.
- Department of Urology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: lw10273mbb@rjlwh.com.cn.
- Department of Urology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: lw10479lx@rjlwh.com.cn.
Förderung
- Shanghai Key Discipline Construction Project
Zitieren
APA
Zhong, Z., Yang, A., Wang, J., Tian, Y., Ma, B., & Liu, X. (2026). Cyclin D1 and the resistance landscape of HIF2 inhibition in clear-cell renal cell carcinoma: Insights from a mini-review. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2026.153305
Vancouver
Zhong Z, Yang A, Wang J, Tian Y, Ma B, Liu X. Cyclin D1 and the resistance landscape of HIF2 inhibition in clear-cell renal cell carcinoma: Insights from a mini-review. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2026.153305
BibTeX
@article{Zhong2026,
author = {Zhong, Zhenbang and Yang, Anqing and Wang, Jinxiang and Tian, Yu and Ma, Binbin and Liu, Xi},
title = {Cyclin D1 and the resistance landscape of HIF2 inhibition in clear-cell renal cell carcinoma: Insights from a mini-review},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
doi = {10.1016/j.bbrc.2026.153305}
}
EUVIMED